FASS logotyp

Peka på symbolerna och beteckningarna till vänster för en förklaring.


Sök apotek med läkemedlet i lager

Sök lagerstatus


Boehringer Ingelheim

Depottablett 0,26 mg
(Vit till benvit, rund med fasade kanter. P1 på ena sidan och Boehringer Ingelheims företagssymbol på andra sidan.)

Medel vid parkinsonism, dopaminagonister

Aktiv substans:
ATC-kod: N04BC05
Läkemedel från Boehringer Ingelheim omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?




Miljörisk: Användning av pramipexol har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Pramipexol är potentiellt persistent.
Bioackumulering: Pramipexol har låg potential att bioackumuleras.

Läs mer

Detaljerad miljöinformation

Predicted Environmental Concentration (PEC):

PEC is calculated according to the following formula:

PEC (μg/L) = (A*109*(100-R))/ (365*P*V*D*100) = 1.5*10-4*A = 0,0008 μg/L


A = 5.1248 kg pramipexol (corresponding to 7,2795 kg pramipexoldihydrokloridmonohydrat total sold amount API in Sweden year 2018, data from IQVIA)

R = 0 % removal rate

P = number of inhabitants in Sweden = 9*106 

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Ref I)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (Ref I)

Predicted No Effect Concentration (PNEC):

Ecotoxicological studies 

Green alga (Desmodesmus subspicatus) (OECD 201) (Ref II):

EC50 72 h (yield) = 26 mg/L

NOEC 72 h (yield) = 1.9 mg/L

EC50 72 h (biomass) = 32 mg/L

NOEC 72 h (biomass) = 4.1 mg/L

EC50 72 h (growth rate) = 240 mg/L

NOEC 72 h (growth rate) = 1.9 mg/L

Water-flea (Daphnia magna) (OECD 202) (Ref III):

EC50 48 h (immobilization) =70 mg/L

NOEC 48 h (immobilization) = 25 mg/L

Zebra fish (Danio rerio) (OECD 203) (Ref IV):

LC50 96 h (mortality) > 100 mg/L (= highest concentration tested)

NOEC 96 h (mortality) = 100 mg/L (= highest concentration tested)

In accordance with the European Technical Guidance Document, the EC50 based on algal growth rate is the more reliable endpoint than the EC50 based on algal biomass. Thus, for comparison with the other species the EC50 based on algal growth rate was considered. With respect to the acute effect studies with the different species, daphnia was the most sensitive species. An assessment factor of 1000 was used for calculation of the PNEC.

PNEC = 70 mg/L / 1000 = 0.07 mg/L = 70 µg/L

Environmental risk classification (PEC/PNEC ratio)

PEC/PNEC = 0,0008 / 70 = 1.0*10-5

Conclusion: PEC / PNEC < 0.1 which justifies the phrase “Use of pramipexole has been considered to result in insignificant environmental risk”.


Aerobic degradation (US-FDA, TAD 3.11) (Ref V)

3.5% mineralization in 28 days

80% primary degradation in 28 days (estimated 50% degradation in 17 days)

Aquatic photodegradation half-life (Ref VI)

pH 5 = 346 hours

pH 7 = 55,5 hours

pH 9 = 33,1 hours

Justification: Pramipexole is degraded photolytically over the range of pH likely to be encountered in the environment indicating that it is readily degraded. However although the aerobic degradation results indicate that significant biodegradation did occur, as 80% of the compound was degraded during the test period, significant mineralization did not occur and pramipexole did not pass the 10 day criteria. The phrase “Pramipexole is potentially persistent” is therefore used.


Partitioning coefficient (OECD 107) (Ref VII):

pH 5 : log D = -2,9

pH 7 : log D = -1.0

pH 9 : log D = 0.7

Justification: Since log D < 4 at pH 7, “Pramipexole has low potential for bioacculumation”.

Excretion / metabolism

Pramipexole is metabolised in man only to a small extent and renal excretion of unchanged pramipexole is the major route of elimination and accounts for about 80% of dose. Approximatly 90% of a 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces (Ref VIII).


  1. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment. Chapter R.10: Characterization of dose [concentration]-response for environment. http://echa.europa.eu/documents/10162/13632/information_requirements_r10_en.pdf

  2. Boehringer Ingelheim GmbH internal report U05-0226, 2005

  3. Boehringer Ingelheim GmbH internal report U05-0219, 2005

  4. Boehringer Ingelheim GmbH internal report U05-0220, 2005

  5. Boehringer Ingelheim GmbH internal report U95-0203, 1995

  6. Boehringer Ingelheim GmbH internal report U96-0120, 1996

  7. Boehringer Ingelheim GmbH internal report U06-0010, 2005

  8. Boehringer Ingelheim GmbH internal report U92-0018, 1991